# Shanghai Junshi Bioscience Co., Ltd.: Phase 3 study started recruiting, 282 planned (Diffuse Large B-Cell Lymphoma)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Sponsor type | Academic and hospital |
| Study | A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT ID | NCT07808827 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Diffuse Large B-Cell Lymphoma |
| Intervention types | combination product |
| Target enrollment | 282 |
| Site countries | China |
| Posted | 2026-09-09 |
| Planned start | 2026-10-08 |
| Event | Started recruiting |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-14 |

## Why this score
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 282 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07808827). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.